Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

53.15
+0.04000.08%
Post-market: 53.150.00000.00%19:18 EDT
Volume:1.40M
Turnover:74.39M
Market Cap:6.55B
PE:14.14
High:53.79
Open:53.18
Low:52.94
Close:53.11
Loading ...

Merck granted review of Halozyme patent claims by PTAB

TIPRANKS
·
03 Jun

Halozyme Therapeutics Price Target Maintained With a $72.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

Halozyme Therapeutics Inc. to Participate in Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
29 May

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (Nivolumab) Co-Formulated With Enhanze® Across Multiple Solid Tumor Indications

THOMSON REUTERS
·
28 May

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Genmab (GMAB) and Vir Biotechnology (VIR)

TIPRANKS
·
22 May

Halozyme Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
15 May

BUZZ-Halozyme falls after Morgan Stanley downgrades

Reuters
·
15 May

Halozyme Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
14 May

Halozyme Therapeutics, Inc : Morgan Stanley Cuts to Equal-Weight From Overweight

THOMSON REUTERS
·
14 May

Halozyme Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
14 May

Halozyme Slides On Potential Revenue Pressure Concerns -- Market Talk

Dow Jones
·
14 May

Big Pharma Counted On a Price Negotiation Loophole. It May Be Closing. -- Barrons.com

Dow Jones
·
14 May

Halozyme Therapeutics Cut to Underperform From Market Perform by Leerink Partners

Dow Jones
·
13 May

Stock Track | Halozyme Therapeutics Plummets 20% After Leerink Partners Downgrades to Underperform

Stock Track
·
13 May

Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47

MT Newswires Live
·
13 May

Halozyme Therapeutics, Inc : Morgan Stanley Raises Target Price to $73.00 From $67.00

THOMSON REUTERS
·
08 May

William O'Neil Initiates Halozyme Therapeutics at Buy

MT Newswires Live
·
08 May

Halozyme Therapeutics Up Over 17%, on Track for Record High Close -- Data Talk

Dow Jones
·
08 May

Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
07 May

Stock Track | Halozyme Therapeutics Soars 8.33% Following Analyst Price Target Hikes

Stock Track
·
07 May